


ORIGINALLY FILED
COPY OF PAPERS

RCE/1600
H

AMENDMENTS TRANSMITTAL LETTER				DOCKET NUMBER: P-IX 2947
SERIAL NO: 09/203,768	FILING DATE: December 2, 1998	EXAMINER: L. Helms	GROUP ART UNIT: 1642	
INVENTION: TUMOR SPECIFIC HUMAN MONOCLOINAL ANTIBODIES AND METHODS OF USE				

TO COMMISSIONER FOR PATENTS
ATTN: Box RCE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Attention Box RCE, Washington, D.C., 20231 on April 5, 2002.

By: 
John T. Murphy, Reg. No. 50,583

April 5, 2002
Date of Signature

Transmitted herewith is a Request for Continued Examination in response to the Office Action mailed January 25, 2002, and the final Office Action mailed May 3, 2001, (in duplicate) in the above-identified application.

Small Entity status of this application has been established under 37 CFR 1.27.

Petition for Extension of Time is enclosed (in duplicate).

Response to Advisory Action mailed January 25, 2002, and the final Office Action mailed May 3, 2001, with attached Appendix A is enclosed.

No additional claims fee is required.

H
J
CD
4-30-02

CLAIMS AS AMENDED

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	48	-	48	-	0	x \$9	\$18	= \$0
INDEPENDENT CLAIMS	14	-	14	-	0	x \$42	\$84	= \$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		YES		X NO	\$140	\$280	= \$0	\$
					TOTAL ADDITIONAL FEE		\$0	\$

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Please charge my Deposit Account No. 03-0370 the amount of \$ 370.00 A duplicate copy of this sheet is enclosed.

TECH CENTER 1600/2900

APR 19 2002

RECEIVED

Inventors: Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
Page 2

A check in the amount of \$830.00 is enclosed, \$370.00 of which covers the request for continued examination fee under 37 C.F.R. § 1.17(e) and \$460.00 of which covers the fee for a three-month extension of time.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 C.F.R. 1.16.


Any patent application processing fees under 37 C.F.R. 1.17.

The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

April 5, 2002

Date


John T. Murphy
Registration No. 50,583
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601



COPY OF PAPER
ORIGINALLY FILED

PATENT
Our Docket: P-IX 2947

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
For: TUMOR SPECIFIC HUMAN
MONOCLONAL ANTIBODIES
AND METHODS OF USE

) Group Art Unit: 1642

) Examiner: L. Helms

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Attention Box RCE, Washington,
D.C., 20231, on April 5, 2002.

By John T. Murphy, Reg. No. 50,583

April 5, 2002

Date of Signature

Box RCE
Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CONTINUED EXAMINATION

This is a request for continued examination of the
above-identified application. 37 C.F.R. § 1.114.

At least one of the following submissions is being
filed herewith:

Amendment or Response
 Declaration or Affidavit
 Information Disclosure Statement

A check in the amount of \$830.00 is being filed
herewith, \$370.00 of which covers the request for continued
examination fee under 37 C.F.R. § 1.17(e) and \$460.00 of which
covers the fee for a three-month extension of time.

APR 19 2002

TECH CENTER 1600/2900

RECEIVED


Inventors: Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
Page 2

The Director is hereby authorized to charge payment or credit any overpayment to Deposit Account No. 03-0370 for any of the following fees: additional filing fees under 37 C.F.R. § 1.16, patent application processing fees under 37 C.F.R. § 1.17, or any fees under 37 C.F.R. § 1.17 that may be required under 37 C.F.R. § 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed for this purpose.

Accordingly, the Applicants respectfully request withdrawal of the finality of the outstanding office action, and consideration of the submission filed herewith. The Examiner is invited to call the undersigned agent or Cathryn Campbell with any questions.

Respectfully submitted,

April 5, 2002
Date


John T. Murphy
Registration No. 50,583
Telephone No. (858) 535-9001
Facsimile No. (858) 535-8949

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601

RECEIVED

APR 19 2002

TECH CENTER 1600/2900



COPY OF PAPERS
ORIGINALLY FILED

PATENT
Our Docket: P-IX 2947


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
For: TUMOR SPECIFIC HUMAN
MONOCLONAL ANTIBODIES
AND METHODS OF USE

) Group Art Unit: 1642

) Examiner: L. Helms

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Attention Box RCE, Washington,
D.C., 20231, on April 5, 2002.

By 
John T. Murphy, Reg. No. 50,583

April 5, 2002
Date of Signature

Box RCE
Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Responsive to the Advisory Action mailed
January 25, 2002, and the final Office Action mailed May 3, 2001,
entry of the following amendments and remarks is respectfully
requested.

AMENDMENTS

150186-1

1. (Thrice amended) A human monoclonal antibody or
functional fragment thereof, comprising the amino acid sequence
of SEQ ID NO:2, or having a conservative substitution of an amino
acid thereof, and the amino acid sequence of SEQ ID NO:4, or
having a conservative substitution of an amino acid thereof,
wherein said antibody or functional fragment thereof binds a
neoplastic cell or antigen thereof.